PRK with MMC as good as LASIK

Article

Wavefront-guided photorefractive keratectomy (PRK) with mitomycin C (MMC) offers very similar results, when correcting compound myopic astigmatism, to wavefront-guided LASIK surgery.

Wavefront-guided photorefractive keratectomy (PRK) with mitomycin C (MMC) offers very similar results, when correcting compound myopic astigmatism, to wavefront-guided LASIK surgery, according to Mauro Campos and colleagues from the Federal University of Sao Paulo, Brazil.

In a prospective, masked, randomized, contralateral eye controlled clinical trial, 84 eyes of 42 patients received customized PRK with MMC in one eye and customized LASIK in the fellow eye. The same postoperative regimens were used in both eyes.

Mean preoperative spherical equivalent (SE) correction was -3.79±1.10 D (PRK) and -3.94±1.18 D (LASIK). At one-year follow-up the percentage of eyes in the PRK group with 0.0, -0.1, -0.2 and -0.3 log MAR uncorrected visual acuity (UCVA) was 13%, 37%, 46% and 4%, respectively and 21%, 54%, 25% and 0%, respectively in the LASIK group. Mean cycloplegic refractive error was +0.48±0.37 D in the PRK group and +0.45±0.54 D in the LASIK group.

The researchers concluded that PRK with MMC is an effective method for correcting compound myopic astigmatism and produces very similar results to wavefront-guided LASIK.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.